Clicky

Inhibikase Therapeutics, Inc.(IKT)

Description: Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of Parkinson's Disease, dysphagia, and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. Its research phase products comprise IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and IkT-148x series of portfolio compounds for use in the treatment of Dementia with Lewy Body and Multiple System Atrophy. The company was founded in 2008 and is headquartered in Atlanta, Georgia


Keywords: Clinical Medicine Parkinson's Disease Neurological Disorders Psychiatric Diagnosis Dementia Stage Pharmaceutical Treatment Of Parkinson's Disease Neurodegenerative Disorders Aging Associated Diseases Pyridines Lewy Body Dementia Multiple System Atrophy Imatinib Dysphagia

Home Page: www.inhibikase.com

IKT Technical Analysis

3350 Riverwood Parkway SE
Atlanta, GA 30339
United States
Phone: 678 392 3419


Officers

Name Title
Dr. Milton H. Werner Ph.D. CEO, Pres & Director
Mr. Joseph Frattaroli CPA Chief Financial Officer
Dr. Roger Rush Head of Preclinical Research
Dr. Surendra Singh Head of Chemistry, Manufacturing & Controls
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. Medical Consultant, CEO of Clintrex Research Corp. & Science Advisor
Dan Williams Controller

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4918
Price-to-Sales TTM: 219.6323
IPO Date: 2020-12-23
Fiscal Year End: December
Full Time Employees: 6
Back to stocks